The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. (April 2014)
- Record Type:
- Journal Article
- Title:
- The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer. (April 2014)
- Main Title:
- The role of epithelial mesenchymal transition and resistance to neoadjuvant therapy in locally advanced rectal cancer
- Authors:
- Bhangu, A.
Wood, G.
Brown, G.
Darzi, A.
Tekkis, P.
Goldin, R. - Abstract:
- <abstract abstract-type="main" id="codi12482-abs-0001"> <title>Abstract</title> <sec id="codi12482-sec-0001" sec-type="section"> <title>Aim</title> <p>Nonresponse to neoadjuvant therapy is a significant challenge for clinicians managing solid cancers. This study aimed to determine whether epithelial mesenchymal transition (EMT) was associated with nonresponse to neoadjuvant therapy in patients with locally advanced rectal cancer.</p> </sec> <sec id="codi12482-sec-0002" sec-type="section"> <title>Method</title> <p>Representative tissue specimens from the tumour‐invasive front of consecutive patients undergoing resection of rectal cancer from 2009 to 2011 were used. Patients with marked regression to neoadjuvant therapy were classified as responders and the remainder were classified as nonresponders. Markers of EMT included reduced immunohistochemical expression of membranous E‐cadherin, increased nuclear beta‐catenin expression and tumour budding. <italic>In‐situ</italic> hybridization was used to assess the expression of microRNA‐200c (mir200c), an upstream master‐regulator of EMT.</p> </sec> <sec id="codi12482-sec-0003" sec-type="section"> <title>Results</title> <p>Of 103 patients undergoing resection of rectal cancer, 69 received neoadjuvant chemoradiotherapy; 65% of these were nonresponders. Reduced expression of mir200c was significantly associated with a higher T grade. Reduced membranous E‐cadherin, increased nuclear beta‐catenin and tumour budding individually<abstract abstract-type="main" id="codi12482-abs-0001"> <title>Abstract</title> <sec id="codi12482-sec-0001" sec-type="section"> <title>Aim</title> <p>Nonresponse to neoadjuvant therapy is a significant challenge for clinicians managing solid cancers. This study aimed to determine whether epithelial mesenchymal transition (EMT) was associated with nonresponse to neoadjuvant therapy in patients with locally advanced rectal cancer.</p> </sec> <sec id="codi12482-sec-0002" sec-type="section"> <title>Method</title> <p>Representative tissue specimens from the tumour‐invasive front of consecutive patients undergoing resection of rectal cancer from 2009 to 2011 were used. Patients with marked regression to neoadjuvant therapy were classified as responders and the remainder were classified as nonresponders. Markers of EMT included reduced immunohistochemical expression of membranous E‐cadherin, increased nuclear beta‐catenin expression and tumour budding. <italic>In‐situ</italic> hybridization was used to assess the expression of microRNA‐200c (mir200c), an upstream master‐regulator of EMT.</p> </sec> <sec id="codi12482-sec-0003" sec-type="section"> <title>Results</title> <p>Of 103 patients undergoing resection of rectal cancer, 69 received neoadjuvant chemoradiotherapy; 65% of these were nonresponders. Reduced expression of mir200c was significantly associated with a higher T grade. Reduced membranous E‐cadherin, increased nuclear beta‐catenin and tumour budding individually predicted the presence of extramural vascular invasion. Reduced E‐cadherin, nucleic beta‐catenin, reduced expression of mir200c and tumour budding were all significantly associated with nonresponse to neoadjuvant therapy (all <italic>P</italic> &lt; 0.001). Reduced E‐cadherin and expression of mir200c were both associated with reduced cancer‐specific survival (log‐rank <italic>P</italic>‐values 0.036 and 0.009, respectively).</p> </sec> <sec id="codi12482-sec-0004" sec-type="section"> <title>Conclusion</title> <p>Targeted biomarkers of EMT were associated with nonresponse to neoadjuvant therapy and reduced survival in advanced rectal cancer. EMT may provide a practical clinical biomarker and a novel therapeutic target to improve the proportion of patients who respond to neoadjuvant therapy.</p> </sec> </abstract> … (more)
- Is Part Of:
- Colorectal disease. Volume 16:Number 4(2014)
- Journal:
- Colorectal disease
- Issue:
- Volume 16:Number 4(2014)
- Issue Display:
- Volume 16, Issue 4 (2014)
- Year:
- 2014
- Volume:
- 16
- Issue:
- 4
- Issue Sort Value:
- 2014-0016-0004-0000
- Page Start:
- O133
- Page End:
- O143
- Publication Date:
- 2014-04
- Subjects:
- Colon (Anatomy) -- Diseases -- Periodicals
Rectum -- Diseases -- Periodicals
616.34 - Journal URLs:
- http://www.blackwell-synergy.com/member/institutions/issuelist.asp?journal=cdi ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/codi.12482 ↗
- Languages:
- English
- ISSNs:
- 1462-8910
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3322.110000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 3329.xml